Indonesia Infectious Disease Drugs Market Analysis Report 2022 to 30

Indonesia Infectious Disease Drugs Market Analysis

$ 3999

Indonesia Infectious Disease Drugs Market valued at $0.71 Bn in 2023, projected to reach $0.95 Bn by 2030 with a 4.27% CAGR. The market is expanding as a result of government initiatives, changing demographics, and an increase in the prevalence of infectious diseases. The market is dominated by key players like Kalbe Farma, Bio Farma, AbbVie Inc., Gilead Sciences, Merck & Co., F. Hoffman-La Roche Ltd., GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, and Novartis AG.

ID: IN10IDPH012 CATEGORY: Pharmaceuticals GEOGRAPHY: Indonesia AUTHOR: Aneri Parekh

Buy Now

Indonesia Infectious Disease Drugs Market Executive Summary

Indonesia Infectious Disease Drugs Market valued at $0.71 Bn in 2023, projected to reach $0.95 Bn by 2030 with a 4.27% CAGR.

The Indonesian Infectious Disease Drugs Market includes treatments for a variety of infectious disorders that are widespread in the country. Due to its tropical climate and dense population, diseases including TB, dengue fever, and malaria present serious health risks in Indonesia. The market includes vaccinations and prophylactics in addition to a variety of antiviral, antibacterial, and antiparasitic drugs. The dynamics of this market are significantly shaped by elements including pharmaceutical laws, healthcare infrastructure, and government initiatives.

Market expansion is being driven by government activities to enhance healthcare infrastructure and medicine accessibility, while pharmaceutical companies are being encouraged to invest in research and development initiatives customized for the Indonesian market due to the growing need for novel treatment choices. The market's major players are concentrating on creating affordable medications and growing their distribution systems to reach more patients throughout the archipelago.

The global pharmaceutical market for infectious diseases was estimated to be worth $118.75 Bn in 2023. This increase is attributable to an increase in diagnoses as well as government-sponsored public education campaigns on infectious disease management and prevention. A shifting market environment is indicated by the growing degree of generic competition. Improving treatment accessibility and removing financial barriers are essential for long-term growth, particularly in developing countries. This will result in additional industrial research and development.

With a market share of more than 20%, Kalbe Farma is a prominent participant in the antibiotics market in Indonesia. The most well-known antibiotic brands offered by the corporation include Concor, Clamox, and Hemavit. Additionally, Kalbe Farma produces and distributes a variety of antiviral medications, such as Favipiravir. Kalbe Farma operates a vast and reputable distribution network across the entirety of Indonesia. This enables the business to provide patients with easy access to its products.

Indonesia infectious disease drugs market

Market Dynamics

Market Growth Drivers:

Infectious diseases are becoming more prevalent in Indonesia, posing issues such as malaria, TB, dengue fever, HIV/ AIDS, and respiratory infections. Effective medications and therapies are in high demand due to the significant burden of these diseases.

Changing Demographics: As a result of lifestyle modifications, urbanization, and population growth, infectious diseases are more likely to spread, which increases the need for medications to contain outbreaks and treat infections.

Government Initiatives: To combat infectious diseases, the Indonesian government has launched several programs and initiatives, such as immunization campaigns and public health awareness campaigns. Government assistance expands healthcare access and treatment funding, which in turn stimulates the market for medications for infectious diseases.

Market Restraints:

Regulatory Barriers: Indonesia's bureaucracy and strict regulations may cause delays in the licensing and release of new medications to treat infectious diseases. This may be a challenge for businesses looking to enter new markets or launch new goods.

High Cost: Many Indonesian patients, especially those from low-income families, may find the high cost of drugs to be prohibitive. Cost concerns could restrict the uptake and application of these medications, affecting the expansion of the market.

Competition from Traditional Medicine: Traditional medicine is still popular in Indonesia, and many people prefer to employ traditional cures for infectious diseases than contemporary drugs. This may present a difficulty for pharmaceutical companies looking to enter the market with new medications.

Healthcare Policies and Regulatory Landscape

The enforcement of local regulations concerning medicines and medical equipment is the responsibility of the Indonesian National Agency of Drug and Food Control, also known as Badan Pengawas Obat dan Makanan (BPOM), which is under the Ministry of Health (MOH) in Indonesia. NA-DFC oversees the review of drug registration applications and grants drug approvals in the form of marketing authorization licenses. Drug clearance procedures can provide challenges for companies due to complex regulatory standards, lengthy review durations, and copious documentation requirements. Pharmaceutical businesses may find the process more difficult to comply with local requirements.

Competitive Landscape

Key Players:

Kalbe Farma
Bio Farma
AbbVie Inc.
Gilead Sciences
Merck & Co.
F. Hoffman-La Roche Ltd.
GlaxoSmithKline plc
Boehringer Ingelheim International GmbH
Janssen Pharmaceuticals
Novartis AG

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Infectious Disease Drug Market Segmentation

By Disease

HIV
Influenza
Hepatitis
Tuberculosis
Malaria
Other

By Treatment

Antibacterial
Antiviral
Antiparasitic
Other

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.